Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 28;12(4):751.
doi: 10.3390/biomedicines12040751.

Molecular and Cellular Involvement in CIPN

Affiliations
Review

Molecular and Cellular Involvement in CIPN

Housem Kacem et al. Biomedicines. .

Abstract

Many anti-cancer drugs, such as taxanes, platinum compounds, vinca alkaloids, and proteasome inhibitors, can cause chemotherapy-induced peripheral neuropathy (CIPN). CIPN is a frequent and harmful side effect that affects the sensory, motor, and autonomic nerves, leading to pain, numbness, tingling, weakness, and reduced quality of life. The causes of CIPN are not fully known, but they involve direct nerve damage, oxidative stress, inflammation, DNA damage, microtubule dysfunction, and altered ion channel activity. CIPN is also affected by genetic, epigenetic, and environmental factors that modulate the risk and intensity of nerve damage. Currently, there are no effective treatments or prevention methods for CIPN, and symptom management is mostly symptomatic and palliative. Therefore, there is a high demand for better understanding of the cellular and molecular mechanisms involved in CIPN, as well as the development of new biomarkers and therapeutic targets. This review gives an overview of the current knowledge and challenges in the field of CIPN, focusing on the biological and molecular mechanisms underlying this disorder.

Keywords: channels; chemotherapy; mechanisms; neuroinflammation; neuropathy.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Schematic figure of main mechanisms of CIPN.
Figure 2
Figure 2
Schematic figure of main actors involved in CIPN.

Similar articles

Cited by

References

    1. Cho Y., Ruddy K.J., Lavoie Smith E.M. Evaluation of Chemotherapy-Induced Peripheral Neuropathy. In: Lustberg M., Loprinzi C., editors. Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy: A MASCC Book. Springer International Publishing; Cham, Switzerland: 2021. pp. 53–93. - DOI
    1. Staff N.P., Grisold A., Grisold W., Windebank A.J. Chemotherapy-Induced Peripheral Neuropathy: A Current Review. Ann. Neurol. 2017;81:772–781. doi: 10.1002/ana.24951. - DOI - PMC - PubMed
    1. Bonomo R., Cavaletti G. Clinical and biochemical markers in CIPN: A reappraisal. Rev. Neurol. 2021;177:890–907. doi: 10.1016/j.neurol.2020.11.001. - DOI - PubMed
    1. Castelli V., Palumbo P., D’Angelo M., Moorthy N.K., Antonosante A., Catanesi M., Lombardi F., Iannotta D., Cinque B., Benedetti E., et al. Probiotic DSF counteracts chemotherapy induced neuropathic pain. Oncotarget. 2018;9:27998–28008. doi: 10.18632/oncotarget.25524. - DOI - PMC - PubMed
    1. Tay N., Laakso E.-L., Schweitzer D., Endersby R., Vetter I., Starobova H. Chemotherapy-induced peripheral neuropathy in children and adolescent cancer patients. Front. Mol. Biosci. 2022;9:1015746. doi: 10.3389/fmolb.2022.1015746. - DOI - PMC - PubMed

LinkOut - more resources